Daniel Schneider, MD
Urology · Quincy, ILNPI 1861786261
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (48.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Valencia Technologies Corporation at 52.4% of the total. Reporting peaked in 2022 at $1,473 and has fallen 83.8% since, to $238 in 2025. That places this record below the midpoint for urology clinicians in IL, where the typical reported total is $2,058.
Across 55 payments — averaging $46.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$1K
- Convatec Inc.$283
- Astellas Pharma US Inc$272
- AbbVie$94
- Olympus America Inc.$54
- Pfizer$46
- plus $463 from 19 others
Across 19 payments — averaging $1950.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$37K
What the payments were for
- Travel & lodging$1,22248%
- Food & beverage$1,05942%
- Education$2409%
- Other$241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 3 | $1,334 |
| Convatec Inc. | 12 | $283 |
| Astellas Pharma US Inc | 6 | $272 |
| AbbVie | 4 | $94 |
| Olympus America Inc. | 3 | $54 |
| Pfizer | 2 | $46 |
| Calyxo, Inc. | 2 | $45 |
| Johnson & Johnson(2 entities) | 2 | $44 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Boston Scientific | 2 | $36 |
| Novartis | 1 | $27 |
| KARL Storz Endoscopy-america | 2 | $26 |
| Welch Allyn | 2 | $24 |
| 180 Medical, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Axonics, Inc. | 1 | $19 |
| Coloplast | 1 | $18 |
| Urogen Pharma, Inc. | 1 | $17 |
| Rochester Medical Corporation | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Merz North America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$1,222
How this compares
$2,546 in reported general payments places this provider in the 50th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 555 | $358,887 |
| MyrbetriqMirabegron | 168 | $86,758 |
| Methenamine Hippurate | 376 | $12,654 |
| Mirabegron ErMirabegron | 24 | $12,133 |
| Tamsulosin Hcl | 996 | $10,188 |
| Potassium Citrate ErPotassium Citrate | 145 | $8,886 |
| Oxybutynin Chloride ErOxybutynin Chloride | 365 | $8,306 |
| Finasteride | 793 | $6,087 |
| Cephalexin | 677 | $4,594 |
| Dutasteride | 127 | $4,095 |
| Testosterone Cypionate | 81 | $4,016 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 108 | $3,913 |
| Silodosin | 50 | $3,665 |
| Testosterone | 32 | $3,452 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 32 | $3,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $358,887555 claims |
| Astellas Pharma US IncMyrbetriq | $272 | $86,758168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 550 urology providers in Illinois.
Other urology in Quincy
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Kevin McVarySpringfield$372K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.